Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.
Celltrion’s newer biosimilars are translating European tender wins and US reimbursement gains into market share, supporting a stronger sales mix and margin expansion heading into the second half.